Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 6/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374404 | 0.89 | APP (0.42) | APPESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL2373672 | 0.89 | APP (0.42) | APPLMNATSHRMAPK1CYP2C19 | |
| SCHEMBL2374622 | 0.89 | APP (0.42) | APP | |
| SCHEMBL2373657 | 0.80 | APP (0.58) | APPESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL2373671 | 0.80 | APP (0.58) | APPESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL2375255 | 0.78 | APP (0.45) | APPMAPT | |
| SCHEMBL2374370 | 0.78 | APP (0.45) | APPMAPT | |
| SCHEMBL2374725 | 0.75 | APP (0.60) | APPMAPTHTTGFERHSD17B10 | |
| SCHEMBL2374401 | 0.69 | APP (0.62) | APPMAPT | |
| SCHEMBL2374407 | 0.69 | APP (0.62) | APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363392-B1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | UNIV PENNSYLVANIA (US) | 2017-05-03 | — | — | EP | disclosed |
| US-8840866-B2 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-23 | — | — | US | disclosed |
| US-8506929-B2 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130129624-A1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-05-23 | — | — | US | disclosed |
| EP-1999109-B1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | UNIV PENNSYLVANIA (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2363391-A1 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | The Trustees of The University of Pennsylvania (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2363392-A1 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | The Trustees of The University of Pennsylvania (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7687052-B2 | radiolabeling; neurodegenerative diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090123369-A1 | Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-20080038195-A1 | radiolabeling; neurodegenerative diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129624-A1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | APP, APBA1, PSEN1 | APP 1/4885ESR1 4860/4885LMNA 1760/4885 |
| US-20080038195-A1 | radiolabeling; neurodegenerative diseases | APP, PSEN1, HTT | APP 1/4885ESR1 4863/4885LMNA 2384/4885 |
| US-20090123369-A1 | Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques | APP, APBA1, PSEN1 | APP 1/4885ESR1 4860/4885LMNA 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.